Pooled data analysis showed that treatment of TB patients with rhuIL-2 expanded the proliferation and conversion of CD4+ and NK cells as well as improved the sputum culture (at 3 months and later) and smear conversion of TB. This evidence concerns the gene CD4 and tuberculosis.